帕立骨化醇与骨化二醇治疗肾移植受者甲状旁腺功能亢进的比较
本研究为6个月、多中心、开放标签、随机临床试验,纳入移植前iPTH 250–600 pg/ml且血钙<10 mg/dl的肾移植受者,比较帕立骨化醇与骨化二醇对继发性甲状旁腺功能亢进的控制效果。意向性分析人群为帕立骨化醇组46例、骨化二醇组47例,主要终点6个月时血清iPTH>110 pg/ml的患者比例两组分别为19.6%和36.2%(P=0.07),但帕立骨化醇组iPTH<70 pg/ml的比例更高(63.4% vs 37.2%,P=0.03)。结论认为两种药物均降低iPTH,但结果不支持使用帕立骨化醇治疗移植后甲状旁腺功能亢进。
要点
- 帕立骨化醇组6个月时iPTH<70 pg/ml比例显著高于骨化二醇组(63.4% vs 37.2%,P=0.03)。
- 主要终点iPTH>110 pg/ml比例两组无显著差异(19.6% vs 36.2%,P=0.07)。
- 骨化二醇组eGFR显著高于帕立骨化醇组,且帕立骨化醇组间质纤维化和小管萎缩有升高趋势。
核心结论
- 帕立骨化醇和骨化二醇均能降低肾移植受者的iPTH,但帕立骨化醇组达到iPTH<70 pg/ml的患者比例更高。
- 结果不支持使用帕立骨化醇治疗移植后甲状旁腺功能亢进。
研究设计与样本
- 6个月、研究者发起、多中心、开放标签、随机临床试验。
- 纳入移植前iPTH 250–600 pg/ml且血钙<10 mg/dl的肾移植受者,随机分为帕立骨化醇组或骨化二醇组。
- 意向性分析人群为帕立骨化醇组46例、骨化二醇组47例。
主要发现
- 主要终点(6个月时血清iPTH>110 pg/ml)在帕立骨化醇组发生率为19.6%,骨化二醇组为36.2%(P=0.07)。
- 帕立骨化醇组iPTH<70 pg/ml的患者比例高于骨化二醇组(63.4% vs 37.2%,P=0.03)。
- 骨转换标志物和骨密度两组无差异。
- 骨化二醇组eGFR显著高于帕立骨化醇组,白蛋白尿无差异。
- 方案活检中间质纤维化和小管萎缩在帕立骨化醇组有升高趋势(48% vs 23.8%,P=0.09)。
关键数值与推荐
- 移植前iPTH 250–600 pg/ml且血钙<10 mg/dl为纳入标准。
- 主要终点为6个月时血清iPTH>110 pg/ml的患者百分比。
临床怎么用
- 对于肾移植后甲状旁腺功能亢进,骨化二醇组eGFR更高且纤维化趋势更低,帕立骨化醇虽降低iPTH更显著但未改善主要终点。
- 临床决策需权衡帕立骨化醇的iPTH降低作用与潜在肾功能和组织学影响。
局限性
- 开放标签设计可能引入偏倚。
- 样本量较小(帕立骨化醇组46例,骨化二醇组47例),主要终点P=0.07未达统计学显著性。
- 6个月随访时间较短,长期结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Secondary hyperparathyroidism (SHPT) and vitamin D deficiency are common at kidney transplantation and are associated with some early and late complications. This study was designed to evaluate whether paricalcitol was more effective than nutritional vitamin D for controlling SHPT in de novo kidney allograft recipients. METHODS: This was a 6-month, investigator-initiated, multicenter, open-label, randomized clinical trial. Patients with pretransplantation iPTH between 250 and 600 pg/ml and calcium <10 mg/dl were randomized to paricalcitol (PAR) or calcifediol (CAL). The intention-to-treat population (PAR: n = 46; CAL: n = 47) was used for the analysis. The primary endpoint was the percentage of patients with serum iPTH >110 pg/ml at 6 months. Secondary endpoints were bone mineral metabolism, renal function, and allograft protocol biopsies. RESULTS: The primary outcome occurred in 19.6% of patients in the PAR group and 36.2% of patients in the CAL group (P = 0.07). However, there was a higher percentage of patients with iPTH <70 pg/ml in the PAR group than in the CAL group (63.4% vs. 37.2%; P = 0.03). No differences were observed in bone turnover biomarkers and bone mineral density. The estimated glomerular filtration rate was significantly higher in the CAL group than in the PAR group without differences in albuminuria. In protocol biopsies, interstitial fibrosis and tubular atrophy tended to be higher in the PAR group than in the CAL group (48% vs. 23.8%; P = 0.09). Both medications were well tolerated. CONCLUSION: Both PAR and CAL reduced iPTH, but PAR was associated with a higher proportion of patients with iPTH <70 pg/ml. These results do not support the use of PAR to treat posttransplantation hyperparathyroidism.
引用
- Cruzado JM, Lauzurica R, Pascual J, et al. Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients. Kidney Int Rep. 2017. PMID: 29340322. doi:10.1016/j.ekir.2017.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。